Results 111 to 120 of about 591 (191)

First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors. [PDF]

open access: yesOncologist
Powderly JD   +9 more
europepmc   +1 more source

First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation. [PDF]

open access: yesJ Clin Oncol
Baldini C   +21 more
europepmc   +1 more source

Exlibris Aulo-Gellio Severino Godinho

open access: yes, 1976
Sprechendes Exlibris.- Rot, orange Sonne gefüllt mit Text.- Inschrift: Exlibris XVI.- Inschrift: Aulo-Congresso .- Inschrift: Gélio Internacional .- Inschrift: Severino de Exlibris.- Inschrift: Godinho Lisoba 1976.- Inschrift: SOL LUCET.- Inschrift: OMNIBUS.- Inschrift: oku 55 ...
openaire   +2 more sources

Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study. [PDF]

open access: yesJ Clin Oncol
Sands J   +22 more
europepmc   +1 more source

Proceedings of the seventh annual Women in Melanoma Conference. [PDF]

open access: yesTher Adv Med Oncol
Najjar YG   +25 more
europepmc   +1 more source

Phase Ib Trial of Bavdegalutamide (ARV-110) in Combination with Abiraterone for Metastatic Prostate Cancer. [PDF]

open access: yesClin Cancer Res
Smoragiewicz M   +17 more
europepmc   +1 more source

Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies. [PDF]

open access: yesJ Immunother Cancer
Sweis RF   +19 more
europepmc   +1 more source

Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial. [PDF]

open access: yesNat Med
Yap TA   +19 more
europepmc   +1 more source

Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. [PDF]

open access: yesNat Med
Kendra KL   +32 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy